Indaptus Therapeutics Inc (INDP) - Net Assets
Based on the latest financial reports, Indaptus Therapeutics Inc (INDP) has net assets worth $3.15 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.31 Million) and total liabilities ($6.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Indaptus Therapeutics Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.15 Million |
| % of Total Assets | 33.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | -91.22% |
| 10-Year Change | -86.12% |
| Growth Volatility | 182.56 |
Indaptus Therapeutics Inc - Net Assets Trend (2008–2025)
This chart illustrates how Indaptus Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See INDP defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Indaptus Therapeutics Inc (2008–2025)
The table below shows the annual net assets of Indaptus Therapeutics Inc from 2008 to 2025. For live valuation and market cap data, see INDP stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.15 Million | -20.11% |
| 2024-12-31 | $3.94 Million | -67.33% |
| 2023-12-31 | $12.08 Million | -50.97% |
| 2022-12-31 | $24.63 Million | -31.39% |
| 2021-12-31 | $35.90 Million | +15202.83% |
| 2020-12-31 | $-237.70K | -102.06% |
| 2019-12-31 | $11.54 Million | -78.46% |
| 2018-12-31 | $53.55 Million | -8.94% |
| 2017-12-31 | $58.80 Million | +158.99% |
| 2016-12-31 | $22.70 Million | -36.28% |
| 2015-12-31 | $35.63 Million | +276.03% |
| 2014-12-31 | $9.48 Million | +1.94% |
| 2013-12-31 | $9.30 Million | +35.68% |
| 2012-12-31 | $6.85 Million | -11.83% |
| 2011-12-31 | $7.77 Million | -32.50% |
| 2010-12-31 | $11.51 Million | +631.58% |
| 2009-12-31 | $1.57 Million | +174.91% |
| 2008-12-31 | $-2.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Indaptus Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6443424700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $21.67K | 0.69% |
| Other Components | $84.42 Million | 2678.58% |
| Total Equity | $3.15 Million | 100.00% |
Indaptus Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Indaptus Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kane Biotech Inc
V:KNE
|
$3.95 Million |
|
Euroespes S.A.
MC:EEP
|
$3.95 Million |
|
SIMFABRIC SA ZY-10
F:853
|
$3.95 Million |
|
Cooper Metals Ltd
AU:CPM
|
$3.95 Million |
|
RENFORTH RESS. INC. NEW
F:9RR
|
$3.95 Million |
|
Raja Ferry Port Public Company Limited
BK:RP
|
$3.94 Million |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
$3.94 Million |
|
THALASSA HLDG.NEW DL-01
F:TH2P
|
$3.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Indaptus Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,944,875 to 3,151,593, a change of -793,282 (-20.1%).
- Net loss of 20,848,916 reduced equity.
- New share issuances of 12,396,888 increased equity.
- Other factors increased equity by 7,658,746.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.85 Million | -661.54% |
| Share Issuances | $12.40 Million | +393.35% |
| Other Changes | $7.66 Million | +243.01% |
| Total Change | $- | -20.11% |
Book Value vs Market Value Analysis
This analysis compares Indaptus Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.38x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $-2.93 | $4.50 | x |
| 2009-12-31 | $1.41 | $4.50 | x |
| 2010-12-31 | $5.58 | $4.50 | x |
| 2011-12-31 | $3.76 | $4.50 | x |
| 2012-12-31 | $3.32 | $4.50 | x |
| 2013-12-31 | $4.50 | $4.50 | x |
| 2014-12-31 | $3.14 | $4.50 | x |
| 2015-12-31 | $365.86 | $4.50 | x |
| 2016-12-31 | $158.66 | $4.50 | x |
| 2017-12-31 | $266.37 | $4.50 | x |
| 2018-12-31 | $137.33 | $4.50 | x |
| 2019-12-31 | $27.32 | $4.50 | x |
| 2020-12-31 | $-0.04 | $4.50 | x |
| 2021-12-31 | $8.78 | $4.50 | x |
| 2022-12-31 | $2.98 | $4.50 | x |
| 2023-12-31 | $1.44 | $4.50 | x |
| 2024-12-31 | $0.42 | $4.50 | x |
| 2025-12-31 | $3.26 | $4.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Indaptus Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -661.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.95x
- Recent ROE (-661.54%) is below the historical average (-136.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.15 Million |
| 2009 | -250.55% | 0.00% | 0.00x | 2.09x | $-4.10 Million |
| 2010 | -47.13% | 0.00% | 0.00x | 1.09x | $-6.58 Million |
| 2011 | -97.58% | 0.00% | 0.00x | 1.17x | $-8.36 Million |
| 2012 | -75.65% | 0.00% | 0.00x | 1.13x | $-5.87 Million |
| 2013 | -54.81% | 0.00% | 0.00x | 1.47x | $-6.02 Million |
| 2014 | -60.09% | 0.00% | 0.00x | 1.32x | $-6.64 Million |
| 2015 | -20.14% | 0.00% | 0.00x | 1.05x | $-10.74 Million |
| 2016 | -58.85% | 0.00% | 0.00x | 1.09x | $-15.63 Million |
| 2017 | -49.16% | 0.00% | 0.00x | 1.10x | $-34.79 Million |
| 2018 | -81.32% | 0.00% | 0.00x | 1.15x | $-48.90 Million |
| 2019 | -412.65% | 0.00% | 0.00x | 1.84x | $-48.75 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.56 Million |
| 2021 | -21.48% | 0.00% | 0.00x | 1.13x | $-11.30 Million |
| 2022 | -58.15% | 0.00% | 0.00x | 1.14x | $-16.79 Million |
| 2023 | -127.71% | 0.00% | 0.00x | 1.24x | $-16.63 Million |
| 2024 | -380.80% | 0.00% | 0.00x | 1.86x | $-15.42 Million |
| 2025 | -661.54% | 0.00% | 0.00x | 2.95x | $-21.16 Million |
Industry Comparison
This section compares Indaptus Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Indaptus Therapeutics Inc (INDP) | $3.15 Million | 0.00% | 1.95x | $3.95 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and h… Read more